论文部分内容阅读
目的研究以万珂为主化学疗法方案提高多发性骨髓瘤初发患者自体外周血造血干细胞采集的作用。方法回顾性分析2006年1月2010年11月4例初发多发性骨髓瘤患者在万珂治疗后自体外周血造血干细胞采集的临床资料。疗效判定依据国际骨髓瘤工作组2006年疗效判断标准。结果经过万珂为主化学疗法方案治疗3~6个疗程(平均4个疗程)后,3例获得CR及以上疗效,均顺利实施了外周血造血干细胞采集;3例采集次数仅1次,1例为2次;平均获得CD34+细胞8.43×106/kg,完全达到采集要求。结论万珂为主化学疗法方案起效快、疗效好,可以提高初发多发性骨髓瘤患者的干细胞采集率。
OBJECTIVE: To investigate the effect of auto-peripheral blood hematopoietic stem cell collection in patients with multiple myeloma who have received chemotherapy based on Velcade. Methods The clinical data of 4 peripheral blood hematopoietic stem cells collected from 4 patients with newly diagnosed multiple myeloma after wanke treatment were retrospectively analyzed from January 2006 to November 2010. Curative effect based on the judgment of the International Myeloma Working Group 2006 curative effect. Results After 3 to 6 courses of treatment (average 4 courses) by 3 Keke chemotherapy-based regimens, 3 patients were treated with CR and above, and peripheral blood stem cell collection was successfully performed. The number of 3 cases was only 1 For example 2 times; on average, CD34 + cells obtained 8.43 × 106 / kg, fully meet the collection requirements. Conclusion Vanke-based chemotherapies have rapid onset and good curative effect, which can improve the collection rate of stem cells in patients with newly diagnosed multiple myeloma.